• Home
  • Search Results
  • Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa.

Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa.

Science translational medicine (2014-11-28)
Noriko Umegaki-Arao, Anna M G Pasmooij, Munenari Itoh, Jane E Cerise, Zongyou Guo, Brynn Levy, Antoni Gostyński, Lisa R Rothman, Marcel F Jonkman, Angela M Christiano
ABSTRACT

Revertant mosaicism is a naturally occurring phenomenon involving spontaneous correction of a pathogenic gene mutation in a somatic cell. It has been observed in several genetic diseases, including epidermolysis bullosa (EB), a group of inherited skin disorders characterized by blistering and scarring. Induced pluripotent stem cells (iPSCs), generated from fibroblasts or keratinocytes, have been proposed as a treatment for EB. However, this requires genome editing to correct the mutations, and, in gene therapy, efficiency of targeted gene correction and deleterious genomic modifications are still limitations of translation. We demonstrate the generation of iPSCs from revertant keratinocytes of a junctional EB patient with compound heterozygous COL17A1 mutations. These revertant iPSCs were then differentiated into naturally genetically corrected keratinocytes that expressed type XVII collagen (Col17). Gene expression profiling showed a strong correlation between gene expression in revertant iPSC-derived keratinocytes and the original revertant keratinocytes, indicating the successful differentiation of iPSCs into the keratinocyte lineage. Revertant-iPSC keratinocytes were then used to create in vitro three-dimensional skin equivalents and reconstitute human skin in vivo in mice, both of which expressed Col17 in the basal layer. Therefore, revertant keratinocytes may be a viable source of spontaneously gene-corrected cells for developing iPSC-based therapeutic approaches in EB.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Ascorbic acid, 99%
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
L-Ascorbic acid, powder, suitable for cell culture, γ-irradiated
Supelco
Ascorbic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Ascorbic acid, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L-Ascorbic acid, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L-Ascorbic acid, ACS reagent, ≥99%
Sigma-Aldrich
L-Ascorbic acid, reagent grade, crystalline
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Supelco
L-Ascorbic acid, analytical standard
USP
Ascorbic acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
L-Ascorbic acid, reagent grade
Ascorbic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Tetrazolium Blue Chloride, used in colorimetric determination of reducing compounds
Sigma-Aldrich
L-Ascorbic acid, meets USP testing specifications
Supelco
L-Ascorbic acid, certified reference material, TraceCERT®
Sigma-Aldrich
L-Ascorbic acid, FCC, FG
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
L-Ascorbic acid, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
Tetrazolium Blue Chloride, indicator for germination, suitable for microbiology, ≥90% (T)
Sigma-Aldrich
L-Ascorbic acid, tested according to Ph. Eur.
Sigma-Aldrich
L-Ascorbic acid, suitable for plant cell culture